For healthcare professionals only.

In R/R MM* patients who have received REVLIMID and bortezomib

Proven OS benefit vs

high-dose dex^1†

Reduced risk of death
vs high-dose dex

MM=multiple myeloma; R/R=relapsed/refractory.

A Foundation of Therapy in MM^2,3

IMNOVID in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 2 prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.²

Patients received a median of 5 lines of prior therapy. At 15.4 month follow-up, IMNOVID + dex median OS was 13.1 months vs 8.1 months with high-dose dex (HR 0.72; P=0.009) (ITT population, N=455).

11/18  INT-POMA180001